Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.
Sjögren’s dry eye requires collaboration between rheumatologists and ophthalmologists for optimal patient management and treatment of this quality-of-life issue.
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue & pain than patients who received placebo.
An expert on peripheral neuropathy shares his practical approach to the diagnosis & management of small fiber neuropathy
This article discusses advances in the diagnosis & treatment of Sjögren’s disease, as well as practical diagnostic tips for clinicians.
After reviewing data from post-marketing observational studies, the FDA has issued new labeling requirements for opioids with the goal of emphasizing and explaining the risks associated with long-term use.
A study from Peene et al. found that patients with primary Sjögren’s disease experienced significant improvements in systemic disease activity and symptoms when treated with intravenous efgartigimod alfa-fcab.
Effective Sept. 1, the brand name drug Stelara will no longer be covered on the UnitedHealthcare commercial plan prescription drug list.
A recent A&R review explores innovative, emerging therapies for the currently incurable, antibody-mediated disease antiphospholipid syndrome.